Evaluating Faricimab for treating eye diseases
Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients
This study is testing if a new eye treatment called Faricimab can help adults with certain eye diseases, like age-related macular degeneration and diabetic macular edema, see better.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University Academic / other |
| Drugs / interventions | faricimab |
| Locations | 1 site (Hanzhou, Zhejiang) |
| Trial ID | NCT06572553 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to assess the efficacy and safety of Faricimab in treating adults with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Participants will receive monthly intravitreal injections of Faricimab for three months, with bi-weekly clinic visits for monitoring. The study focuses on improving visual acuity and understanding any medical issues related to the treatment. Faricimab is a bispecific antibody targeting both VEGF-A and Ang-2, potentially offering enhanced treatment outcomes for these retinal conditions.
Who should consider this trial
Good fit: Ideal candidates include Chinese adults aged 18 and older diagnosed with nAMD, DME, or RVO.
Not a fit: Patients with active ocular inflammation, those receiving other anti-VEGF therapies, or unable to provide necessary clinical data may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve vision and quality of life for patients with these retinal diseases.
How similar studies have performed: Other studies have shown promise with similar dual-pathway approaches, indicating potential for success with Faricimab.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Chinese patients aged 18 years or older and of any gender; 2. Patients who have been diagnosed with nAMD, DME or RVO by OCT, FFA, ICGA or OCTA; 3. Patients whose decision to receive treatment with faricimab was made prior to and independent of study participation; 4. Patients who have received at least one treatment with faricimab during the course of the study; 5. have signed an informed consent form. Exclusion Criteria: 1. Active ocular inflammation or suspected active ocular infection in either eye; 2. Receipt of any other anti-VEGF therapy after faricimab; 3. Patient is unable to provide clinical data (visual acuity and OCT images) within 2 weeks (14 days) prior to receiving the initial faricimab injection; 4. Currently participating in any other clinical trial.
Where this trial is running
Hanzhou, Zhejiang
- 2 nd Affiliated Hospital, School of Medicine, Zhejiang University, China — Hanzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Panpan Ye, doctor
- Email: yepanpan@zju.edu.cn
- Phone: +86 13806506267
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.